Phase II trial of perioperative chemotherapy with cisplatin and dose dense paclitaxel in patients with stage Ib2-IIb uterine cervical cancer (SGSG013)
Not Applicable
- Conditions
- Cervical cancer patients with clinical stage Ib2, IIa with tumor diameter >=4cm, IIb
- Registration Number
- JPRN-UMIN000006440
- Lead Sponsor
- Sankai Gynecology Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1) Usage of other experimental drugs, phenytoin or flucytosine 2) History of serious drug allergy or hypersensitivity with cisplatin or paclitaxel 3) Massive ascites, ileus 4) Active infection 5) Peripheral neuropathy grade 2-4 6) Unstable angina, myocardinal infarction within 6 months or serious arrthymia 7) Interstitial pneumonia or fibrosis 8) Double cancer 9) No coexisting severe medical conditions such as uncontrollable diabetes mellitus, hypertension or bleeding 10) Pregnancy or lactation 11) Mental disease 12) Continuus usage of steroid 13) Bilateral hydronephrosis 14) Judged as inappropriate to participate this trial by investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method